Immunolight LLC, a biotech company, collaborated with Duke on a revolutionary cancer therapy that required expertise in chemistry, radiation physics, photonics, and other fields. When the decade-long project struggled with logistics such as tech transfer, management of funds, and lack of scientific direction, the investigators turned to CTSI.
“This was the perfect opportunity to bring in project management and oversight,” said Dr. Barry Myers, Director of Innovation at CTSI.
The therapy is now advancing to clinical trials. “If anything, we got to where we’re at now because of CTSI,” said Wayne Beyer, VP at Immunolight.